Identity alignment note — not a separate therapy grade

TB500 / Tβ4 Acetate Alignment

Aligns checklist “TB500 (Thymosin B4 Acetate)” to the Ac-LKKTETQ fragment drawer — do not merge full Tβ4.

Editorial review:

What evidence says

Evidence snapshot

This drawer marks papers. It is not a plan, a dose, or a source. A paper is a bounded report. It is not a protocol. Grades name the object. They are not a safety rating.

Purpose. Checklist and shop-style labels often print “TB500 (Thymosin B4 Acetate)” next to TB-500. This note aligns those strings to the existing TB-500 fragment drawer without merging objects and without rewriting tb-500.md or built/tb-500.*.

Identity lock (site). On this site, TB-500 means the N-acetyl heptapeptide fragment Ac-LKKTETQ (actin-binding region of thymosin β4). Fragment CAS 885340-08-9; PubChem CID 62707662. Full-length thymosin β4 is a different molecule — CAS 77591-33-4; PubChem CID 45382195. Never print full Tβ4 CAS 77591-33-4 as the TB-500 fragment identity. “TB500 (Thymosin B4 Acetate)” is an ambiguous marketing string — it may intend the fragment, full Tβ4 acetate, or neither. Require CoA / sequence / intact mass before treating a vial as Ac-LKKTETQ. This alignment note is not a second therapy grade and does not merge into the fragment drawer.

Bottom line

Live fragment drawer (tb-500) already locks Ac-LKKTETQ and grades fragment-specific analytical / doping / metabolism papers separately from full-length Tβ4 clinical work. Honest line: controlled human efficacy for the Ac-LKKTETQ fragment is not established there. Full-Tβ4 dry-eye or venous-ulcer trials are related ≠ fragment proof. This alignment pack does not re-litigate those grades and does not expand tb-500.md.

Papers

Fragment Ac-LKKTETQ / commercial “TB-500” (identity and analytics) — from live fragment drawer context

PMID 22962027 — Esposito 2012

Tested: chemical identification of N-terminal acetylated Tβ4 fragment Ac-LKKTETQ in a product labeled TB-500, with synthetic confirmation (doping-suspected preparation).

Does not show: human therapeutic efficacy. Establishes what that commercial object contained in the analyzed sample.

PMID 23084823 — Ho 2012

Tested: LC-MS doping-control methods for TB-500 described as a synthetic N-acetylated LKKTETQ segment of Tβ4 in equine urine and plasma.

Does not show: a human healing trial. Detection method paper.

PMID 38382158 — Rahaman 2024

Tested: quantification of TB-500 (Ac-LKKTETQ) and metabolites in in-vitro systems and in rats; in-vitro wound-healing activity screening of parent versus metabolites.

Does not show: a controlled human fragment trial.

PMID 36482504 — Delcourt 2023

Tested: analytical characterization of misbranded/adulterated products marketed as TB500/TB1000 (and related), not a clinical intervention.

Does not show: efficacy. Underscores identity and labeling risk.

Related short peptide (LKKTETQ — not the same as Ac-LKKTETQ)

PMID 12581423 — Philp 2003

Tested: full-length thymosin β4 and a synthetic seven-amino-acid actin-binding peptide LKKTETQ (acetylation not the named object here) in dermal wound models in diabetic and aged mice.

Does not show: a human result, or that commercial Ac-LKKTETQ TB-500 is the same tested article as unacetylated LKKTETQ.

PMID 20179146 — Sosne 2010

Tested: review of biological activities of Tβ4 mapped to short active-site peptide sequences (including actin-binding domain peptides).

Does not show: a controlled human Ac-LKKTETQ drug trial.

Full-length thymosin β4 (different object — do not grade as TB-500 fragment)

PMID 26056426 — Sosne 2015

Tested: thymosin β4 ophthalmic solution versus placebo in a randomized Phase II dry-eye trial (full Tβ4).

Does not show: an Ac-LKKTETQ fragment result, or a systemic “TB-500” claim.

PMID 17495250 — Guarnera 2007

Tested: clinical remarks on a European prospective randomized topical thymosin β4 study in venous ulcers (full Tβ4).

Does not show: fragment Ac-LKKTETQ efficacy.

What is not established

That checklist wording “TB500 (Thymosin B4 Acetate)” equals Ac-LKKTETQ without CoA. Equivalence of fragment, unacetylated LKKTETQ, and full-length Tβ4. Any approved fragment indication. This alignment note does not rewrite the live fragment drawer and does not create a merged full-Tβ4 therapy grade.

Selected sources

22962027 23084823 38382158 36482504 12581423 20179146 26056426 17495250

What people discuss

Reported experiences

Reported topics are not established benefits.

Watch for

Risks and unknowns

Context matters. Approval of one medicine, formulation, or use does not establish approval of products sold online or other uses. This page is educational and does not provide dosing or treatment advice.

Member discussion

Compare experiences with care.

Before posting: Describe firsthand observations and uncertainty. Do not prescribe, arrange transactions, or post private health information.

◎Verified members

Join the discussion

Verified members can contribute to compound conversations.

No approved member reports yet. Thoughtful first contributions are welcome.